Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences
19 Agosto 2024 - 3:05PM
Cocrystal Pharma, Inc.’s (Nasdaq: COCP) management announces its
participation in the upcoming Virtual Investor Summit Microcap
Forum in August and the H.C. Wainwright 26th Annual Global
Investment Conference in September.
“We look forward to showcasing key near-term
clinical milestones at two upcoming investment conferences,” said
James Martin, CFO and co-CEO of Cocrystal. “We expect to report
topline results in 2024 from our influenza A Phase 2a challenge
study with our novel oral PB2 inhibitor CC-42344 with the final
report expected to be filed in 2025. We also expect to report
topline results from the Phase 1 multiple-ascending cohorts in late
2024 or early 2025 with our novel oral protease inhibitor CDI-988
for the treatment of norovirus and coronavirus infections.”
Virtual Investor Summit Microcap
Forum
- The presentation and Q&A
session will begin Tuesday, August 20, 2024 at 9:00 a.m. Eastern
time
- Investors can register here to view
the live presentation and to ask questions
H.C. Wainwright
26th Annual Global Investment
Conference
- An on-demand presentation will be
available to conference participants on the H.C. Wainwright
platform beginning Monday, September 9, 2024 at 7:00 a.m. Eastern
time
- Management will be available for
in-person and virtual one-on-one meeting throughout the conference;
institutional investors and industry professionals can register to
attend the conference virtually or in-person at the Lotte New York
Palace
- The presentation will be available
on the Company’s website
CC-42344 – Pandemic and Seasonal
Influenza A PB2 Inhibitor CC-42344 is our novel,
broad-spectrum antiviral candidate to treat pandemic and seasonal
influenza A. CC-42344 inhibits influenza A’s viral replication by
binding to a highly conserved PB2 site. We discovered CC-42344
using our proprietary structure-based drug discovery platform. We
are conducting a Phase 2a influenza challenge study in the United
Kingdom to evaluate safety and efficacy in healthy volunteers.
CC-42344 demonstrated favorable safety and tolerability, and
pharmacokinetics profiles in a Phase 1 study. In vitro testing
indicated CC-42344’s potent antiviral activity against influenza A
strains as well as against pandemic and seasonal strains and
strains resistant to Tamiflu® and Xofluza®.
CDI-988 – Pan-viral Protease Inhibitor
Against Noroviruses and CoronavirusesWe have developed a
novel protease inhibitor, CDI-988, to treat norovirus and
coronavirus infection, including SARS-CoV-2 and its variants.
CDI-988 was specifically designed and developed as an oral
broad-spectrum antiviral inhibitor using our structure-based drug
discovery platform to bind to a highly conserved region of
noroviruses, coronaviruses and other 3CL viral proteases. CDI-988
is being evaluated in a randomized, double-blind,
placebo-controlled Phase 1 trial for safety, tolerability and
pharmacokinetics.
About Cocrystal Pharma,
Inc.Cocrystal Pharma, Inc. is a clinical-stage
biotechnology company discovering and developing novel antiviral
therapeutics that target the replication process of influenza
viruses, coronaviruses (including SARS-CoV-2), noroviruses and
hepatitis C viruses. Cocrystal employs unique structure-based
technologies and Nobel Prize-winning expertise to create first- and
best-in-class antiviral drugs. For further information about
Cocrystal, please visit www.cocrystalpharma.com.
Cautionary Note Regarding
Forward-Looking StatementsThis press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
regarding the potential characteristics and efficacy of product
candidates and the expected timing and results of the clinical
trials for such product candidates. The words "believe," "may,"
"estimate," "continue," "anticipate," "intend," "should," "plan,"
"could," "target," "potential," "is likely," "will," "expect" and
similar expressions, as they relate to us, are intended to identify
forward-looking statements. We have based these forward-looking
statements largely on our current expectations and projections
about future events. Some or all of the events anticipated by these
forward-looking statements may not occur. Important factors that
could cause actual results to differ from those in the
forward-looking statements include, but are not limited to, risks
relating to our ability to proceed with and complete clinical
trials including recruiting volunteers and procuring materials for
such studies by our clinical research organizations and vendors,
the results of such studies, our and our collaboration partners’
technology and software performing as expected, general risks
arising from clinical studies, receipt of regulatory approvals,
regulatory changes, and potential development of effective
treatments and/or vaccines by competitors, including as part of the
programs financed by the U.S. and foreign governments, potential
mutations in a virus we are targeting that may result in variants
that are resistant to a product candidate we develop. Further
information on our risk factors is contained in our filings with
the SEC, including our Annual Report on Form 10-K for the year
ended December 31, 2023. Any forward-looking statement made by us
herein speaks only as of the date on which it is made. Factors or
events that could cause our actual results to differ may emerge
from time to time, and it is not possible for us to predict all of
them. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by
law.
Investor Contact:LHA Investor
RelationsJody Cain310-691-7100jcain@lhai.com
Media Contact:JQA PartnersJules
Abraham917-885-7378Jabraham@jqapartners.com
# # #
Cocrystal Pharma (NASDAQ:COCP)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Cocrystal Pharma (NASDAQ:COCP)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024